100 percent insulin remission

LCT today released latest Russian trial results with the second patient achieving a 100% insulin remission result using only 20% dosage. This is an amazing result and will be heard around the world. Get aboard now as the NZ trials will start soon.

Living Cell Technologies Ltd
PO Box 3014, Auburn VIC 3123
ABN: 14 104 028 042
COMPANY ANNOUNCEMENT
Further Positive Preliminary Data on DiabeCell® Phase I/IIa Trial
22 October 2007, Auckland, New Zealand and Melbourne, Australia: Living Cell Technologies Ltd
(ASX:LCT, OTC: LVCLY) is releasing this update on the excellent initial responses observed in its
DiabeCell® trial in Russia to ensure that the information is available to all shareholders, following
the preliminary announcement on October 9th.
Medical Director of LCT, Professor Bob Elliott, advises that two patients have been implanted with
their first dose of DiabeCell® and are due for a second dose 6 months later. DiabeCell® is
administered to patients without the need for immunosuppressant drugs.
The first patient was injected with his first dose in June 2007 without adverse effects. Control of
blood glucose levels has been maintained while his daily insulin requirement was gradually
reduced by about 40% over the past 4 months.
The second recipient was implanted with her first dose of DiabeCell® in September 2007 without
adverse effects and control of blood glucose has been maintained with progressive reduction of
daily insulin requirements. At one month following the implant, the patient has been weaned off
insulin altogether.
“These early stage results have exceeded our expectations, with one patient no longer
dependant on insulin therapy following the smallest dose of DiabeCell®,” said Professor Bob
Elliot, Medical Director of LCT.
LCT CEO, Dr Paul Tan says, “This outstanding result increases the prospects of DiabeCell® as an
effective commercial product for diabetes.”
The object of the phase I/IIa trial in Russia is to determine whether a small dose of live microencapsulated
pig islets injected into the abdominal cavity of type I diabetic patients is safe and
can produce enough insulin to have a measurable effect on improving the control of blood
glucose levels.
In the trial at the Sklifasovsky Institute in Moscow, each of 6 patients is to receive two
transplants of the smallest dose (5,000 islet equivalents (IEQ’s) which is equivalent to one third
of the maximum dose (15,000 IEQ’s) planned for testing in the proposed New Zealand study.
However, this is very preliminary data and LCT management looks forward to assessing these
results in the context of full clinical trial data.
For further information: www.lctglobal.com
Paul Tan
CEO
Mob: 0402 716 984 (AUS)
021 608 784 (NZ)
Tel: +64 9 270 7941
Prof Bob Elliott
Medical Director
Mob: +64 272 924 177
Media Relations
Daniella Goldberg
Buchan Consulting
P:+ 612 9237 2803
M: 0416 211 067 (AUS)
[email protected]